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NUEDEXTA (dextromethorphan/quinidine) is the only FDA and EMA approved PBA 
treatment. The primary objective of this analysis is to evaluate healthcare utili-
zation and costs in PBA patients before and after dextromethorphan/quinidine 
treatment. For this analysis type of service unit utilized and overall utilization 
are both functions of cost. METHODS: Retrospective analysis using anonymized 
patient level data from a large national health insurer. Claims data (both commercial 
and Medicare) were assessed for each eligible patient, for an observation period 
including the 12 months before (baseline) and 12 months after (follow-up) the Index 
Date, defined as the first prescription fill date for dextromethorphan/quinidine. 
Eligibility requirements were an Index Date between January 1, 2007 through August 
31, 2013, and continuous insurance eligibility for the entire 24 month observation 
period . RESULTS: A cohort of 1245 patients treated with dextromethorphan/qui-
nidine was identified; 488 of whom met eligibility requirements. Mean healthcare 
costs, primarily driven by utilization, were reduced in the 12 months following 
dextromethorphan/quinidine use compared with the 12 months pretreatment, 
including reduction of inpatient costs (27%), emergency room visits (19%), stroke-
related postcare (73%) and ancillary costs (2%). Pre-index costs were not reflective 
of costs related to acute stroke treatment in stroke patients, as no patient had a 
stroke during the 12-month pre-index (baseline) period. Despite the added prescrip-
tion cost of dextromethorphan/quinidine, the overall weighted mean cost reduc-
tion was 5%. CONCLUSIONS: Patients treated with dextromethorphan/quinidine 
(NUEDEXTA) showed a decrease in healthcare utilization and costs compared to 
the pre-index period.
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OBJECTIVES: To evaluate multiple sclerosis (MS)-related health care resource 
utilization and costs prior to and after initiating natalizumab in 
Germany. METHODS: A retrospective claims database analysis was conducted 
using the Health Risk Institute research database to identify MS patients ini-
tiating natalizumab (index date) between 1/1/2009 and 12/31/2012. Patients 
had 24 months of continuous enrollment (12 months before [pre-period] and 
12 months after [post-period] the index date) and at least one natalizumab pre-
scription in the 4th quarter after the index date. Furthermore, patients with and 
without other disease-modifying treatment (DMT) during the pre-period were 
examined. Patient characteristics, MS-related inpatient stays, and corticos-
teroid use were compared in both periods using paired statistical tests, where 
appropriate. RESULTS: The study included 193 patients, mean age 37.1 years 
(standard deviation 10.2), 64.8% female. The majority (75.1%) used a DMT dur-
ing the pre-period. After initiating natalizumab, there was a significant reduc-
tion in the percentage of patients with MS-related inpatient stays (49.7% 
versus 14.0%, P< 0.001), MS-related inpatient costs (mean € 3,759 versus 
€ 815, P< 0.001), and length of stay (mean 7.0 days versus 2.7 days, P< 0.001) 
compared to the pre-period. In patients without pre-period DMTs, there was a 
significant reduction in the percentage of patients with MS-related inpatient stays 
(–77.3% P< 0.001) and costs (-€ 3052.0; P< 0.001) and patients with DMTs in the pre-
period showed similar significant reductions (–70.2% and –€ 2908.2, respectively, 
P< 0.001 for both). Compared to the pre-period, there were significant reductions 
in corticosteroid use for all natalizumab initiators (–62.3%, P< 0.001), which cor-
responded to a mean corticosteroid cost-per-patient reduction of –€ 290.75 across 
all natalizumab users (P< 0.001). CONCLUSIONS: In Germany, the initiation of 
natalizumab was associated with significant decreases in MS-related inpatient 
stays, and corticosteroid use with corresponding decreases in the average length of 
stay and costs among natalizumab users with and without DMTs in the prior year.
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OBJECTIVES: sIBM is a progressive idiopathic inflammatory myopathy characterized 
by atrophy and weakness of proximal and distal muscle groups; knee extensors and 
wrist/finger flexors and dysphagic processes are frequently involved. Progressive 
weakness results in loss of independence and need for assistive devices and sup-
portive care. The progressive nature of sIBM leads to increasing medical expenses, 
many of which are not covered by third-party payers, making quantification difficult 
using existing databases. SMART-sIBM, a self-report tool, was developed to better 
characterize out-of-pocket expenses and non-reimbursable items not captured by 
health care systems. METHODS: SMART-sIBM was developed based on in-depth 
interview data from 20 sIBM patients, review of existing resource-use measures, 
and input from clinical experts (n= 9). SMART-sIBM captures resource utilization 
and costs of sIBM over a 6-month, retrospective recall period, including out-of-
pocket costs and third-party payer expenses. A cross-sectional study (n= 102 sIBM 
patients) was conducted in the US to gather preliminary resource utilization and 
patient financial data. Draft versions were reviewed by clinical experts and patients 
independently, and were refined before use in the cross-sectional study. RESULTS: 
Patients had a mean age of 66 years, disease duration of 1-18 years, and varied physi-
cal limitations. All patients reported need for frequent health care visits, and 80% 
indicated need for house/vehicle modifications and purchase of assistive equipment 
to accommodate sIBM-related disabilities. Nearly one-third of patients required 
paid help with household tasks, while more than one-half relied on help from 
unpaid caregivers (e.g., spouse, friend). Nearly half (45%) reported changes in job 
status because of sIBM-related functional limitations. CONCLUSIONS: Results of 
comparison to evaluate the efficacy and safety, with the study of Jiao and cols., an 
hypothetical cohort were placed in accordance with this efficacy and the Hoehn 
and Yahr states, an analysis of incremental cost-effectiveness ratio (ICER) was 
performed. We used a markov model to estimate the CE and performed sensitivity 
analyses and varying disease progression parameters and costs. The outcome of 
effectiveness was life years gained. RESULTS: For patients with early PD in mono-
therapy, treatment with levodopa had lower costs and more effectiveness than 
pramipexole, rasagiline and selegiline treatments. With a time horizon of 5 years, 
levodopa was 5.04 life years gained and cost $236,750.52, the cost of selegiline 
was $247,094.21 with 4.1 life years gained, pramipexol had a cost of $247,420.46 
with 4.1 life years gained and finally rasagilina $254,006.56 with 3.17 life years 
gained, all values of ICER were less than one GDP per capital. This results showed 
that levodopa was the dominant alternative. The sensitivity analyses confirm the 
results. CONCLUSIONS: Findings of this study indicate that levodopa provides 
the major effectiveness and the lower cost compared to pramipexole, rasagiline 
and selegiline as first treatment option in patients with early Parkinson disease 
(measured by UPDRS) in monotherapy.
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OBJECTIVES: Lisdexamfetamine dimesylate (LDX) demonstrated efficacy in terms 
of reduced binge eating days per week in adults (18-55 years old) with binge eating 
disorder (BED) in 2 randomized control trials (RCTs). This study examined the cost-
effectiveness of LDX compared to placebo for the treatment of adult BED patients 
in the United States (U.S.). METHODS: A decision-analytic Markov cohort model 
comparing LDX to placebo was developed using 1-week cycles and a 52-week time 
horizon. Based upon the 5th Edition of the Diagnostic and Statistical Manual of 
Mental Disorders criteria of BED, the model comprised the following health states: 
non-symptomatic BED, sub-threshold BED, mild BED, moderate BED and severe 
and extreme BED. Model parameter estimates including transition probabilities, 
utility values and resource utilization were obtained from RCTs, a survey, and lit-
erature. All cost data were inflated to 2013. The primary outcome was incremental 
cost-effectiveness ratio (ICER). The base case analysis assumed a 12-week course 
of treatment, based upon RCTs’ treatment duration. RESULTS: Patients on LDX 
therapy gained 0.0064 quality-adjusted life years (QALY) compared to patients on 
the NPT arm, while the average total cost was $175 higher for LDX therapy. LDX 
therapy yielded the ICER of $27,512 per QALY gained vs placebo and was shown to 
be cost-effective given a willingness-to-pay threshold of $50,000. CONCLUSIONS: 
Treatment of BED with LDX showed an increase in QALYs at an acceptable cost and 
considered cost-effective at the commonly used willingness-to-pay thresholds in 
the U.S. There is a need to generate additional scientific evidence supporting long-
term benefits of LDX therapy for BED.
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OBJECTIVES: To evaluate the cost-effectiveness of glatiramer acetate (COPAXONE®) 
for relapsing-remitting multiple sclerosis (RRMS) compared to interferons-β (IFNs) 
in scenarios with and without routine testing for the presence of neutralizing anti-
bodies (NAbs) in people receiving IFNs. NAbs reduce the therapeutic benefits of 
interferons-β (IFNs). Glatiramer acetate does not develop NAbs. METHODS: The 
impact of NAb testing was evaluated using a Markov model previously developed 
for the Netherlands. The model followed patients over 50 years through 21 health 
states: Expanded Disability Status Scale (EDSS) 0-9 for patients with RRMS and 
secondary progressive multiple sclerosis, respectively, and death (EDSS 10). Baseline 
demographics, transition probabilities, treatment-specific relative risks, and utility 
values were obtained from published literature. Health resource use was based on 
the products’ Summary of Product Characteristics and treatment guidelines. 2014 
unit costs were based on national tariffs and published data from the Netherlands. 
The analysis was conducted from the societal perspective. RESULTS: In the scenario 
without routine NAb testing total treatment costs of glatiramer acetate were lower 
versus most IFNs. It also resulted in higher number of quality-adjusted life-years 
compared to all IFNs as some IFN patients received ineffective treatment. In the 
scenario with routine NAb testing total treatment costs of all IFNs were higher 
than in the other scenario and higher than glatiramer acetate due to switching to 
more expensive treatments than first-line injectables. In both scenarios glatiramer 
acetate was dominant against most IFNs. CONCLUSIONS: In both scenarios where 
NAb testing is routine practice or not, glatiramer acetate is less costly and more 
effective versus interferon-β -1a 44mcg, 30mcg, and 22mcg for RRMS.
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OBJECTIVES: Pseudobulbar affect (PBA) is an underdiagnosed condition character-
ized by sudden, involuntary episodes of crying and/or laughing in patients with 
traumatic brain injury or certain neurologic diseases, including multiple sclerosis, 
amyotrophic lateral sclerosis, stroke, Alzheimer’s disease, and others. Studies sug-
gest that PBA symptoms are associated with added healthcare utilization and costs. 
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claim date was designated as the index date. Continuous health plan enrollment 
12 months pre- and post-index date was required. Patients were assigned to four 
monotherapy AED cohorts based on drug class: sodium channel blockers (SCs), 
gamma-aminobutyric acid analogs (GABAs), synaptic vesicle protein 2A binding 
(SV2) and multiple mechanisms (MMs). Adherence was assessed using the propor-
tion of days covered (PDC) and persistence was defined as days to discontinua-
tion with an allowable treatment gap of 45 days without the index AED. Logistic 
and Cox proportional hazards models were used to compare the results among 
the cohorts. RESULTS: Patients in the SC cohort had significantly lower baseline 
Charlson Comorbidity Index scores (1.82), indicating that they were healthier than 
those in the GAMA (2.08, p< 0.001) and SV2 (2.46, p< 0.001) cohorts. Patients in the SC 
cohort were significantly less likely to have a baseline psychiatric disorder (37.6%) 
than those in the GABA (63.8%, p< 0.001) and MM (52.1%, p< 0.001) cohorts. Patients 
treated with GABAs (OR= 0.44, p< 0.001) and MMs (OR= 0.63, p< 0.001) were signifi-
cantly less likely to adhere to their medications (PDC < 80%) than those treated 
with SC. Furthermore, patients treated with GABAs (hazard ratio [HR]= 1.74; 95% 
confidence interval [CI]= 1.59-1.90) and MMs (HR= 1.18; 95% CI= 1.07-1.29) were more 
likely to discontinue treatment during the follow-up period compared to those in the 
SC cohort. CONCLUSIONS: Patients treated with Sodium channel blockers are more 
likely adhere to treatment and have lower discontinuation of AED monotherapy 
than those treated with GABAs and MMs.
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OBJECTIVES: This study examined the relationship between medication adherence 
and outcomes in multiple sclerosis (MS), where both concepts are more difficult to 
measure than in diseases like hypertension where most medications are taken orally 
and surrogate outcomes (e.g., blood pressure) are routinely collected. METHODS: 
MS patients age ≥ 18 years treated at Geisinger Clinic and taking an MS medication 
were surveyed three times, six months apart, to assess medication adherence and 
MS outcomes. Patients reported their doses taken in the past month (adherence), 
number of relapses, TQSM medication satisfaction score, and MSIS physical and 
psychological functional scores. Nonparametric bootstrap analyses were used to 
compare mean outcome scores among patients with and without missed doses. A 
sub-analysis on patients with Geisinger insurance claims was conducted to calcu-
late patient’s MS medication possession ratio (MPR) from 2004 to 2013 and compare 
this claim-based adherence measure with the other results. RESULTS: 306 patients 
completed 971 surveys. Most patients were white (99%), female (85%), ages 22 to 76 
years old (median 50 years). Median time since initial MS diagnosis was 11 years. 
Mean self-reported adherence was 90% (median= 100%, IQR= 92-100%). Most patients 
(80%) reported zero relapses. Patients with no missed doses had significantly higher 
medication satisfaction than those with missed doses (77.5 vs. 72.5, p= 0.0006) and 
better psychological function (32.7 vs. 37.7, p= 0.017). There were no significant dif-
ferences between groups in reported number of relapses or physical functional 
status. MPR could only be calculated for 95 patients (37 had claims but not enough 
to calculate MPR), was extremely high in this subgroup (mean 96%, median 98%) 
and did not show the same associations with patient outcomes. CONCLUSIONS: 
Medication adherence in the actively treated MS population is very high, whether 
measured by self-report or MPR. Patients with 100% adherence showed evidence of 
better medication satisfaction and psychological function than others.
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OBJECTIVES: Whole genome sequencing (WGS) can be used to predict future dis-
ease risk or inform treatment. Current guidelines suggest only reporting variants 
that are clinically actionable. Reporting incidental or non-actionable findings could 
generate anxiety and unnecessary medical tests, but patients could miss valu-
able information if not reported. Over-treatment may occur by acting on findings 
prematurely, potentially causing harm and unnecessary resource use. We measure 
the value of WGS information using contingent valuation methods. METHODS: An 
online pilot survey (n= 26 adults from US general population) was used to evaluate 
willingness to pay for a basic WGS report (recommended by guidelines), and genetic 
information excluded from the basic report (non-actionable findings) to inform a 
national survey. Respondents were initially asked whether they would purchase a 
basic WGS report for a specified dollar amount. A follow-up question increased or 
decreased cost of the report based on the initial response. Responses were used 
to identify ranges of willingness to pay for a basic report for each respondent. The 
same steps were followed to identify ranges for respondents’ willingness to pay 
for information excluded from the WGS report. The initial costs in the questions 
were randomized across respondents. RESULTS: 42% of respondents (n= 11) were 
not willing to pay anything for the basic report, and no respondent was willing to 
pay more than $1000 for the basic report. Most respondents (n= 17, 65%) were not 
willing to pay anything for non-actionable genetic information, and only one person 
reported being willing to pay more than $400 for this information. CONCLUSIONS: 
A large number of participants perceived that genetic information can be harmful, 
as shown by respondents’ lack of interest in this information even if it were free. 
Our findings also suggest that respondents were willing to pay more for actionable 
genetic information than for non-actionable findings.
this study demonstrate, for the first time, the high resource utilization and financial 
burden experienced by sIBM patients in the USA. Further data collection of this 
type is needed to better understand the true economic burden of sIBM not only 
in US but globally.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
studies
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OBJECTIVES: Describe medication utilization patterns of migraine prophylactics 
in commercially insured patients. METHODS: Adult migraineurs (ICD-9 code 346.
XX) newly initiating migraine prophylactics (no claims for 12 months before first 
(index) prophylactic prescription) between January 2007 and March 2013 were identi-
fied from the OptumInsight employer claims database and followed for 6 months. 
Prophylactics included antiepileptics (topiramate, divalproex, valproic acid), beta-
blockers (propranolol, timolol), antidepressants (amitriptyline) and onabotulinum-
toxinA. Continuous enrollment was required for 12 months pre-index and 6 months 
post-index. To increase the specificity of migraine prophylactics, patients with prior 
diagnoses for conditions for which their prescribed prophylactics were also indi-
cated (i.e., epilepsy for antiepileptics, hypertension/congestive heart failure for beta-
blockers, and depression for amitriptyline) were excluded. Outcomes of interest were 
medication adherence (medication possession ratio [MPR]), discontinuation (> 30-day 
gap between prescriptions), and switching patterns. Time to discontinuation of initial 
prophylactic was described using Kaplan-Meier curves. RESULTS: 19,881 patients 
initiated prophylactic treatment with 12,136 (61%), 3,037 (15%), 4,163 (21%), and 545 
(3%) patients initiating antiepileptics, beta-blockers, amitriptyline, and onabotuli-
numtoxinA, respectively. Mean (SD) MPR for any prophylactic was 0.49 (0.31) (0.34 
(0.27)—valproic acid to 0.67 (0.22)—onabotulinumtoxinA) with a mean (SD) of 89.2 
(56.7) days on treatment over 6 months. Discontinuation rates were high ranging from 
74% (topiramate and onabotulinumtoxinA) to 90% (valproic acid). Switching rates 
ranged from 6% (topiramate) to 20% (valproic acid). Between 46% (topiramate) and 
68% (timolol) patients discontinued treatment after the first prescription, and median 
days to discontinuation of initial treatment ranged from 30 (valproic acid, divalproex, 
timolol, amitriptyline) to 84 days (onabotulinumtoxinA). CONCLUSIONS: Adherence 
to migraine prophylactic medications was poor with about 50% of patients discontinu-
ing after their first prescription and over 75% discontinuing within 6 months. The large 
proportion of patients discontinuing after first prescription suggests further research 
is needed on reasons for discontinuation and better tolerated therapies.
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OBJECTIVES: To review the methods currently used to measure adherence to 
oral and injectable disease modifying therapies (DMTs) in multiple sclerosis (MS) 
patients. METHODS: A systematic literature search was conducted using PubMed, 
CINAHL, PsychINFO, and Cochrane Library to identify articles assessing adherence 
to DMTs. The publication time frame was from January 2004 to November 2014. 
Studies were included if they focused on at least one U.S. FDA-approved injectable 
or oral DMT, assessed DMT adherence as either a primary or secondary outcome, 
reported DMT adherence rate(s), and included details of the method(s) used to 
calculate adherence level or proportion of adherers/non-adherers. RESULTS: A 
total of 36 studies met inclusion criteria. The majority (63.9%) of studies were con-
ducted in the U.S. All studies assessed adherence to at least one injectable DMT, 
while two studies also included an oral DMT. Twenty-two studies used a cross-
sectional, randomized controlled, or prospective observational study design. Among 
these studies, Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ), 
Medication Event Monitoring System (MEMS), adherence diary, self-reported sur-
vey items (designed specifically for respective study), Morisky 4-item medication 
adherence scale (MMAS-4), and self-reported missed dose ratios were used to assess 
adherence. Fourteen studies employed a retrospective design, using medication 
possession ratios (MPRs) and proportion of days covered (PDC) to assess adher-
ence. Although some of the measures (e.g., MEMS, MMAS-4, MPR, PDC) are well 
established, several of the self-reported items lack any evidence of reliability and 
validity. CONCLUSIONS: A plethora of methods have been used to assess DMT 
adherence, and each has its own unique advantage and disadvantage. The wide 
array of measurement methods and adherence definitions makes it difficult to 
compare adherence rates across studies.
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OBJECTIVES: To evaluate patient adherence and persistence to anti-epileptic drug 
(AED) monotherapy. METHODS: Adult patients (age> 18 years) with ≥ 2 epilepsy 
diagnosis claims (ICD-9-CM:345) or one epilepsy diagnosis claim and one claim for 
other convulsion (ICD-9-CM: 780.39) were selected from the U.S. Veterans Health 
Administration database (01OCT2008-30SEPT2013). Patients were required to 
have ≥ 1 AED prescription post-epilepsy diagnosis, and the first AED prescription 
